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Abstract. Background/Aim: Activin and its antagonist
follistatin (FST) have been implicated in several solid tumours.
This study investigated the role of FST in breast cancer.
Materials and Methods: FST expression was examined using
reverse transcription polymerase chain reaction (RT-PCR),
real-time quantitative polymerase chain reaction (qPCR) and
immunohistochemistry in a cohort of breast cancer samples.
Expression was correlated to pathological and prognostic
parameters in our patient cohort. FST was overexpressed in
MCF-7 cells and assays for growth and invasion were
performed. Results: FST is expressed in breast tissue, in the
cytoplasm of mammary epithelial cells. Expression was
decreased in breast cancer tissue in comparison to normal
mammary tissue. Over-expression of FST in vitro led to
significantly increased growth rate and reduced invasion.
Higher FST associates with lower-grade tumours and better
survival. Conclusion: Our results suggest a role for FST as a
suppressor of invasion and metastasis in breast cancer.
Follistatin (FST) is a secreted extracellular regulatory protein
that binds activin and, with less affinity, related TGFβ
superfamily members such as bone morphogenetic proteins
(BMPs), preventing access to their receptors (1, 2).
Originally thought to act on the pituitary to regulate FSH
release, FST has subsequently been noted in many other
tissues, in particular co-localising with activin resulting in
autocrine and paracrine cellular regulation (1, 3). As an
antagonist of activin, FST has diverse regulatory roles in
embryogenesis, tissue differentiation and repair, gonadal
function and inflammatory and immune processes (3, 4).
Three major FST isoforms can be produced, namely FST288
(from splice variant mRNA precursor FST317), FST315
(from splice variant mRNA precursor FST344) and a third
FST isoform, FST303, produced from the post-translational
truncation of the FST315 C-terminus (5). These three main
FST isoforms can also be glycosylated to yield six further
FST isoforms (6). FST288 and FST315 are differentially
expressed in human tissues, but FST315 is the predominant
isoform, whilst the FST288 isoform accounts for less than
5% of the encoded mRNA (6, 7) .
The FST/activin interaction has been implicated in tumour
proliferation, angiogenesis and metastasis in several solid
tumours (8-11). Activin has primarily been seen as an
inhibitor of cellular proliferation, although certain cell
populations seem to be stimulated by activin. Thus, the
overall result of activin/FST action in cancer may be both
context and cell type specific (3, 6). 
In the breast, FST is expressed in the normal mammary
gland and in different breast proliferative diseases, with
additional experimental evidence suggesting that FST can
modulate the breast cancer cell cycle (3, 12-14). However,
its role in breast cancer growth and metastasis is far from
clear. In this study we demonstrated a clinical correlation
between FST expression and survival in breast cancer, and
that overexpression of FST in vitro reduces invasion of
breast cancer cells.
Patients and Methods
Cell lines and patient tissue samples. Human breast cell lines MCF-
7,MDA MB 231, ZR-751, BT 549 and BT-20 were obtained from
and cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% foetal calf serum and antibiotics (PAA
Laboratories Ltd., Somerset, UK). Cells were incubated at 37˚C in
5% CO2 at 95% humidity.
Breast cancer tissue and normal breast tissue samples were
collected during surgery at the University Hospital of Wales. In
total, 93 tumour samples and 30 normal breast tissue samples were
obtained from patients who were enrolled in the study. The tissues
obtained during surgery were snap-frozen in liquid nitrogen and
stored at −80˚C. The presence of tumour cells was verified by a
pathologist (Anthony Douglas-Jones). Background tissues were
confirmed to be free of tumour deposits. The median follow-up time
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was 120 months. All human specimens and data were obtained
according to a protocol reviewed and approved by the local ethical
committee, and all patients signed an informed consent form.
Immunohistochemistry and antibodies. Frozen sections of breast
tumours and background breast tissue were cut at a thickness of 6
μm. Sections were air-dried and fixed in a mixture of 50% acetone
and 50% methanol before a rehydration using Tris-buffered saline
(TBS) buffer for 20 min. The sections were then incubated for 20
min in a 0.6% bovine serum albumin TBS and probed with FST
antibody (1:100 dilution, sc-23553, Santa Cruz Biotechnology, TX,
USA) for 1 h at room temperature. Following three washes with
TBS, sections were incubated for 30 min with a secondary
biotinylated antibody (1:1,000, Multi Link Swine anti-goat/
mouse/rabbit immunoglobulin; Dako Inc., Ely, Cambridgeshire, UK).
Avidin/Biotin Complex (Vector Laboratories Ltd, Peterborough, UK)
was then applied before a subsequent incubation with the chromogen
3, 3’-diaminobenzidine (Vector Laboratories Ltd.) in the dark for 
5 min, and were then counterstained in Gill’s haematoxylin.
Reverse transcription, PCR and real-time PCR. RNA was isolated
using the TRI Reagent from Sigma (USA) according to the
manufacturer’s instructions. RNA quantification was carried out using
a spectrophotometer. RNA (0.5 μg) was reverse transcribed into cDNA
using a standard reverse transcription kit. The quality of generated
cDNA was verified using GAPDH primers (Table I). Reaction
conditions started with an initial denaturation of 5 min at 94˚C followed
by 35 cycles of 10 sec at 94˚C, 30 sec at 55˚C for annealing and 30 sec
at 72˚C, with a final elongation of 72˚C for 10 min. Amplified products
were then separated on a 1% agarose gel and stained using Sybr safe
DNA gel stain (Thermo Scientific UK Ltd., Loughborough, UK).
Transcript levels of FST in the breast tissue specimens were
determined using real-time PCR as reported previously (15). An
additional sequence (5’-actgaacctgaccgtaca-3’) was added to the
antisense primer which is complementary to the universal Z probe
(Intergen Inc., Oxford, UK). The reaction was carried out using
iCycler iQ™ (Bio-Rad, Hemel Hempstead, Hertfordshire, UK),
which is equipped with an optical unit that allows real-time
detection of 96 reactions. The sequences of the primers used in the
current study are listed in Table I.
FST over-expression model. Full-length FST344 was amplified from
a cDNA library of normal human prostate tissue and was then cloned
into a mammalian expression plasmid vector (TOPO TA pEF/His,
Invitrogen Inc., Paisley, UK). The constructed FST expression plasmid
vector was verified using DNA sequencing. For the overexpression
experiments, MCF-7 cells were transfected with the constructed FST
expression plasmids or an empty pEF plasmid respectively.
Transfected cells were selected using 5 μg/ml blasticidin for a period
up to two weeks. Selected cells were subject to verification using real
time PCR before further use in the experiments. 
Cell growth assay. The growth of the breast cancer cell lines was
assessed using a colorimetric-based method. 3×103 cells were
seeded per well on a 96-well plate. Cells were fixed on day one,
three, and five in 4% formaldehyde. Following staining with 0.5%
crystal violet, the crystal violet was extracted using 10% acetic acid
and the absorbance was read at a wave length of 540 nm. Growth
rate was calculated using a formula, Growth rate (%)=absorbance
(Day 3 or Day 5)/absorbance (Day1) ×100.
Cell invasion assay. Cell invasion assays were performed using
inserts with 8-μm pores coated with 50 μg Matrigel (BD
Biosciences, San Jose, CA, USA). Cells (2×105) were added to
transwell inserts on top of the artificial basement membranes, and
into 24-well plate as control. After three days incubation inserts
were fixed with formalin and stained with crystal violet. The
Matrigel and cells remained in the inserts were removed using a
cotton swap. Crystal violet stained invaded cells were quantified by
extraction of stain using 10% acetic acid. The invasion was
measured using invasion rate, i.e. absorbance of invaded cells/
absorbance of corresponding control ×100 (%). 
Statistical analysis. Analysis of the data was performed using
SigmaPlot 11 (Systat Software, San Jose, CA, USA). Medians were
compared using the Mann-Whitney U-test for non-normally
distributed data, while means were compared using the two-sample
t-test for normally distributed data. Kaplan Meier survival curves
were produced from online expression databases KMplot (16) and
Gene Expression Miner (17). Gene Expression Miner also used
publically available expression data to produce a boxplot correlation
of FST mRNA level with tumour grade.
Results
FST is expressed in a variety of normal tissues, cancer tissues
and human breast cancer cell lines. As one might expect for a
protein originally related to gonadal function and development,
FST was expressed in the ovary. In our data it was also seen at
a lower level in normal breast and colon. It was not expressed
in bone, liver or skin (Figure 1A). This correlates well with
gene expression data from the recent review by Shi et al. (6).
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Table I. Primers used for PCR and QPCR.
Primer                                        Forward primer                                                             Reverse primer
FST (QPCR)                             ACCTGAGAAAGGCTACCTG                                  ACTGAACCTGACCGTACACAACCTTGAAATCCCATAAA
FST344                                      TGAGGGAAAGTGTATCAAAGCAAA                   TCGGTGTCTTCCGAAATGGAG
FST317                                      AAGTGTATCAAAGCAAAGTCCTGT                     ATGGCTCAGGTTTTACGGGC
GAPDH (PCR)                         GGCTGCTTTTAACTCTGGTA                                 GACTGTGGTCATGAGTCCTT
FST344 (CDs)                           ATGGTCCGCGCGAGGCA                                       TTACCACTCTAGAATAGAAGATATAGG
In human breast cell lines, both FST317 and FST344 were
seen in MDA-MB-231 and BT-549 cells. Lower expression
levels of both were seen in MCF-7 and BT-20 lines. In ZR-
751 cells FST344 was more strongly expressed than FST317
(Figure 1B).
Follistatin is seen in the cytoplasm and nucleus of mammary
epithelium and is reduced in invasive breast carcinoma.
Immunohistochemical staining was shown to be more intense
for FST in the cytoplasm of normal mammary epithelial
cells, as well as the nucleus. As the cells become more
invasive, through ductal carcinoma in situ (DCIS) to invasive
carcinoma, the staining reduces in intensity (Figure 2). This
is in agreement with other studies (12, 18), one of which
noted a decrease in FST transcripts on qPCR of invasive
ductal carcinoma tissue samples compared to normal tissue.
Overexpression of follistatin in MCF-7 cells increases
proliferation. The constructed FST expression plasmid was
successful at producing a 3.5-fold increase in FST expression
in the transfected MCF-7 cells (Figure 3A). Our cellular
growth assay (n=3) demonstrates a significant increase in
proliferation in MCF-7 with FST overexpression compared
to control MCF-7 pEF cells (Figure 3).
Overexpression of follistatin in MCF-7 cells reduces
invasion. Invasion assay (n=3) showed that in comparison to
pEF control, MCF-7 cells overexpressing FST showed
significantly decreased invasion (Figure 3).
Low follistatin expression in the clinical cohort is associated
with higher histological grade and poorer survival. The use
of publically-available expression databases with clinical
parameters, such as KMplot allow the collation of
expression data to give a larger cohort of patients. This data
shows that high FST expression in breast cancer tumours is
associated with better relapse free survival (Figure 4A).
There was no correlation between survival and FST
expression in the KMplot analyses of subgroups of patients
according to receptor status or lymph node positivity, which
correlates with our cohort regarding lymph node status and
FST expression (Table II). High FST expression was
significantly correlated with better overall survival at 5
years (Figure 4B, p=0.007), but became less statistically
significant over 10 and 20 years survival (Figure 4C and D,
p=0.06 both). This may reflect the smaller numbers of
patients in the cohort over a longer follow up period, but
raises an interesting possibility that low FST marks more
aggressive disease. 
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Figure 1. Expression of follistatin in human tissues and breast cancer cell lines. (A) The expression of follistatin transcripts in different human
tissues using RT-PCR. L is DNA ladder. 1-4 are placenta. 5-7 are ovary. 8 and 9 are normal breast tissues. 10 is omentum. 11 is liver. 12 and 13
are skin. 14 is colon. 15 is bone. 16 and 17 are breast cancer tissue. 18 and 19 are prostate cancer tissues. 20 is negative control. (B) Follistatin
transcript splicing variants (FST344, NM_013409.2 and FST317, NM_006350.3) were detected in five breast cancer cell lines, i.e. MCF-7, MDA-
MB-231, ZR-751, BT-549 and Bt-20, using RT-PCR.
Furthermore, the qPCR transcript levels in our patient
cohort showed that FST expression was decreased in
undifferentiated and more aggressive higher grade tumours
(Table II and Figure 5A). Geneminer data also support the
finding (Figure 5B). Our cohort also showed that those with
poor prognostic features such as high TNM stage and high
Nottingham prognostic index score had lower FST transcript
levels (Figures 5C and 6), however, this did not consistently
reach significance. Interestingly, low FST transcript levels
appeared to be associated with death from breast cancer and
bone metastases (p=0.05 both). 
Discussion
Activin and BMPs are both TGFβ superfamily members, that
employ different combinations of serine-threonine kinase
receptors that when phosphorylated, result in activation of
canonical Smad 2/3 and Smad 1/5/8 intracellular signalling
pathways respectively (19-21). Non-canonical Akt/PI3K,
MAPK/ERK and Wnt/β-catenin pathways can also be
activated, dependant on the combination of receptors recruited.
Consequently, TGFβ, activin, and BMPs engage in a complex
signalling network, resulting in the transcription of target
genes with vital influences on cell growth, differentiation,
proliferation and survival. It is not surprising therefore, that
these proteins are implicated in tumorigenesis (19-22).
FST is a known transcription target of activin signalling
(23) and acts as a negative feedback regulator, binding
activin with high affinity to prevent its interaction with
activin receptors and inhibiting its biological cellular
functions (4, 6). Due to this regulatory influence, follistatin
has also been implicated in tumourigenesis in certain solid
tumours (6). Some studies have examined the role of activin
in breast cancer, however, very little is known regarding the
influence of follistatin in breast cancer.
Our results show variation in FST expression, with MDA-
MB-231, ZR-751 and BT-549 cells expressing FST at a higher
level than MCF-7 and BT-20 cells. It is possible that
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Figure 2. Immunochemical staining of follistatin in human breast carcinomas, ductal carcinoma in situ (middle) and invasive ductal carcinoma
(right) in comparison to normal breast tissues (left).
differential FST expression amongst the cell lines reflects the
heterogeneous nature of breast cancer and its molecular
subtypes. The most clinically-relevant subtypes are those breast
cancers that express oestrogen receptor (ER), progesterone
receptor (PR) or human epidermal growth factor receptor 2
(HER2), as this determines treatment options and prognosis.
Prior studies provided evidence for an interaction between
downstream activin signalling pathway components, and ER
signalling in breast cancer cells (24, 25). One study (25) found
activin and oestrogen signalling in breast cancer cells can be
mutually repressive at a transcriptional level. Kalkhoven et al.
(26) established that the presence of ER in breast cancer cells
influences whether these cells are growth inhibited by activin.
They determined ER-positive cell lines were growth inhibited
by treatment with activin, with ZR-751 cells being the most
sensitive, whereas the ER-negative cell lines were resistant to
the growth-inhibitory potential of activin. In BT-20 cells this
resistance to activin signalling was thought to be related to low
activin receptor levels, however, this was not the case in MDA-
MB-231 cells, in which activin binding to receptors was
detected despite their resistance to the anti-proliferative effect
of activin, suggesting the effect is downstream of the activin
receptors. Conversely, others have found that activin treatment
inhibits the growth of both ER positive and negative cell lines
(27). This study also demonstrated that the growth inhibition
of activin was abrogated to a greater degree by the addition of
follistatin treatment in ER negative cells, compared to ER
positive cells. They show MDA-MB-231 cells actually secrete
more follistatin than MCF-7 cells and suggest that this auto and
paracrine signalling may be the reason that MDA-MB-231
cells are more resistant to activin effects on cellular growth.
Follistatin has also been reported as being more highly
expressed in ER negative tumours (13). 
In our data FST is highly expressed in MDA-MB-231,
BT-549 and ZR-751 cells, and less so in MCF-7 and BT-20
cells, which may reflect the different levels of activin
pathway activity between the cell lines, different degrees of
dysregulation in the activin pathways or crosstalk with other
signalling pathways such as hormone receptors, that can alter
FST transcription. This added layer of complexity in relation
to follistatin and activin signalling in breast cancer certainly
warrants more detailed exploration, particularly in relation
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Figure 3. FST overexpression model and functional assays. (A) FST344 expression plasmid produced a 3.5-fold increase in FST expression compared
to pEF control plasmid in the transfected MCF-7 cells. (B) Invasion assay demonstrating a significantly reduced invasion rate in FST-overexpressing
MCF-7 cells compared to control (p<0.001). (C) Percentage growth rate at day three of the assay, with significant increase in growth rate in FST
overexpressing MCF-7 cells compared to control (p<0.0001). (D) This is maintained at day five of growth assay (p<0.0001).
to loss of hormone receptor expression, treatment resistance
and progression of disease.
Activin is well-documented as slowing-down cell
proliferation in breast cancer studies (26). Burdette et al.
observed that activin treatment arrested T47D breast cancer
cells in the G0-G1 cell cycle. This effect was abrogated either
by using the type I receptor inhibitor SB431542, or an
adenoviral dominant negative Smad3, or treatment with
follistatin. When they treated the cells with follistatin alone,
cells proliferated and accumulated in S phase, when
compared to untreated cells (28). This is certainly supported
by our data, which shows that overexpressing FST in MCF-
7 breast cancer cells increases proliferation and growth. FST
has also been seen at increased levels of expression in benign
proliferative breast disorders such as fibroadenoma (12). 
Interestingly, in a study that used a SCID murine model
inoculated with FST288 expressing R30C mammary cells, the
FST-expressing tumours were smaller in volume compared to
control, or those expressing activin. This seemed to be as a
result of increased apoptosis in the FST tumours (3). So,
although FST may result in increased growth and
proliferation of breast cancer cells, the rate of cellular death
may also increase, such that in vivo, the tumours are smaller.
On the other hand, BMP-promoted angiogenesis may also be
involved, but is yet to be investigated  in this context.
Our results are the first report that FST decreases
invasiveness in breast cancer cells. Thus, these findings can
only be indirectly supported by other studies such as Bashir et
al. (18), who treated MCF-7 cells with activin, and found an
increase in epithelial to mesenchymal transition (EMT) and
decreased E-cadherin expression, implying a tendency to
greater invasiveness. Both activin and TGFβ have been seen
to promote EMT (18, 29). In vivo, a murine model has shown
MCF-7 cells overexpressing activin establish tumours with
more mesenchymal transition features compared to control
tumours (18). We might, thus, expect higher FST levels to
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Figure 4. Correlation of FST expression to patient survival. (A) Relapse-free survival is better in tumours with higher FST expression (p<0.001).
(B) Overall patient survival over 5 years follow-up shows significantly better survival in those with higher FST expression (p=0.007). (C) Overall
patient survival over 10 years and (D) 20 years follow-up do not reach statistical significance in terms of survival difference (p=0.06), but does
show a similar trend regarding better survival with higher FST expression.
antagonise this effect of activin and reduce EMT and invasive
properties. Follistatin also directly binds to TGF-β3 and
completely blocks TGF-β3-induced EMT of the normal murine
mammary gland (NMuMG) epithelial cell line in vitro (29).
This inhibition of EMT by FST is reflected in our clinical data,
that low FST expression correlates with higher grade tumours,
which typically display more aggressive and invasive clinical
behaviour and are histologically less well differentiated. In our
cohort FST protein was decreased in invasive breast cancer
compared to normal tissue, supported by Bashir et al., who
found qPCR transcript levels of FST were significantly lower
in breast tumours (18) which may indicate reduction in FST
expression as invasive characteristics develop. Conversely,
publically available mRNA expression EST data (see Shi et al.
(6)) suggests an increased expression of FST in breast cancer
as compared to normal mammary tissue and Bloise et al. report
no significant difference on semi-quantitative scoring of FST
expression in normal mammary tissue versus in situ and
invasive carcinoma (12). Of course this variability can be
accounted for by differing size and tumour characteristics of
the patient cohorts and the different experimental methods
utilised. Mange et al. (30) found relative secretion of FST was
increased in tumourigenic MCF10.DCIS and MCF10.CA1d
cells compared to non tumourigenic MCF10A cells. They then
determined, using enzyme-linked immunosorbant assay
(ELISA) that serum concentration of FST was higher in
invasive breast cancer patients compared to healthy matched
controls. The breast cancer patients were predominantly
histological grade one and two, ER positive, and of small size,
suggesting FST serum levels increase in early breast cancers
with better prognostic features compared to healthy controls,
but does not allow us to conclude what the serum levels in
those with more advanced disease may be.
We have correlated higher tumour FST expression with better
survival, particularly in the first 5 years of follow-up, suggesting
that FST may have a protective role in regards to progression
and metastasis of breast cancer that is worthy of further
exploration. The increase in cellular proliferation and decreased
invasiveness in breast cancer cells in relation to higher
expression of FST that we have demonstrated suggests a dual
role in tumourigenesis for FST. A balance between proliferation
and differentiation is coordinated by TGFβ ligands and their
antagonists. This is well recognised in TGFβ family members,
such as TGFβ itself which, similarly to activin, is known to
have inhibitory effects on cellular proliferation in several
cancers, but is also associated with EMT, invasion and
metastasis in aggressive and progressive disease (19, 22).
The most frequent metastatic site in breast cancer is the bone,
resulting in osteolytic lesions that cause significant morbidity
and reduce survival (31). As an antagonist of BMPs, which are
regulators of bone development and implicated in development
of bone metastases in several solid tumours (20), FST may also
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Table II. Tumour cohort FST expression levels. 
                                                               Patient number                        Mean transcripts                    Standard deviation                               p-Value
                                                                        (N)                           (copies per 50 ng RNA)
Prognosis                                                                                                                                                                                                                   
  NPI-1                                                             58                                            102.9                                          56.5                                                
  NPI-2                                                             34                                              99.8                                          54.2                                              0.97
  NPI-3                                                             15                                              24.5                                          12.5                                              0.18
Node status                                                                                                                                                                                                                
  Node (–)                                                        58                                            102.9                                          56.5                                                
  Node (+)                                                        49                                              76.8                                          37.9                                              0.69
Histological Grade                                                                                                                                                                                                    
  1                                                                     19                                            397                                           184                                                   
  2                                                                     36                                              29.4                                          13.4                                              0.0165
  3                                                                     55                                              32.9                                          12                                                 0.0169
TNM Stage                                                                                                                                                                                                                
  1                                                                     62                                            135.8                                          60                                                   
  2                                                                     34                                              51.1                                          22                                                 0.19
  3                                                                       7                                              11.54                                          5                                                 0.042
  4                                                                       4                                              39.6                                          38                                                 0.19
Follow-up
  Disease free                                                   81                                            117.2                                          46                                                   
  With metastasis                                               6                                              33.5                                          24                                                 0.12
  With local recurrence                                     4                                              82.3                                          80                                                 0.72
  Died of breast cancer                                    16                                              21.8                                          12                                                 0.050
NPI, Nottingham prognostic index.
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Figure 5. Expression of FST is associated with tumour grade and TNM staging. A) FST qPCR transcript levels from our clinical cohort according
to patient’s histological tumour grade. The X axis represents tumour grade, a reflection of how differentiated and therefore how ‘aggressive’ it’s
potential for invasion. Grade 1 is well differentiated, Grade 2 is moderately differentiated, whilst Grade 3 is poorly differentiated tumour. Those
with grade 2 and 3 tumours had lower FST levels than grade 1 (p=0.0165 and 0.0169 respectively). B) Gene expression miner uses publicly available
patient expression data from patient breast cancer tissue. Low FST expression correlated with higher grade, poorly differentiated breast tumours
(p<0.0001), similar to our cohort in panel A. C) FST qPCR transcript levels according to TNM staging. Those tumours that are TNM stage 1 (i.e.
smaller size, with less nodal and distant metastases) had higher FST expression than TNM 2, 3 and 4 (p=0.19, 0.042 and 0.19 respectively).
have a role to play in metastasis to bone specifically. Our
clinical cohort demonstrated a significantly lower expression of
FST in primary tumours that metastasised to bone.
Overexpression of another BMP antagonist Noggin in breast
cancer cells, is associated with the potential to develop
osteolytic lesions in bone (32). And when looking at serum
markers in breast cancer patients (33), activin levels were
reported to be significantly increased in breast cancer compared
with age-matched control donors, those with bone metastases
having significantly higher levels than patients without.
Kang et al. (34) found follistatin overexpression to be
part of a bone metastasis gene signature in a subpopulation
of MDA-MD-231 cells, which included overexpression of
CXCR4, MMP1, FGF5, CTGF, and IL-11. This bone
metastasis signature differed from that of adrenal metastasis
gene signature. However, Kang et al. demonstrated only one
potential bone metastasis gene signature-there may well be
several others in which overexpression of FST is not
utilised. Overexpression of FST may also emerge later in
the course of the disease, and thus may not be reflected in
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Figure 6. A) FST qPCR transcript levels according to patient’s Nottingham Prognostic Index level. Those with lower FST has a poorer prognostic
score, but this does not reach significance (p=0.18). B) FST qPCR transcript levels according to disease outcomes showing those that died from
their disease have a lower FST expression compared to those remaining disease free (p=0.05). C) and D) FST expression transcripts were higher
in those remaining disease-free compared to those with poor prognosis (all though this did not reach significance p=0.09) and those with bone
metastases (p=0.054).
the expression profile of the patient’s primary tumour.
Nevertheless, these initial investigations raise significant
interest in the role of follistatin specifically in bone
metastases.
Taken together, we suggest that FST has varying potential
roles in breast cancer development, progression, invasion and
metastasis that are worthy of note and further elucidation.
From our data, FST over-expression appears to promote in
vitro proliferation and reduce invasiveness. Higher FST
expressing tumors are associated with improved patient
survival, and FST may thus prove a potential prognostic and
therapeutic target in breast cancer. 
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